Pages
Products
scFv(CD19)-CD28-CD3zeta CAR-T Lentivirus

scFv(CD19)-CD28-CD3zeta CAR-T Lentivirus

Cat.No. :  LVG00003Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Gene Informationn

Cat. No. LVG00003Z
Description Lentivirus particles containing second generation of anti-CD19 CAR (chimeric antigen receptor) scFv-CD28-CD3zeta.
Target Gene CD19
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Gene Name
Gene Symbol
Synonyms
Gene ID
UniProt ID
mRNA Refseq
Chromosome Location
Function
Pathway
MIM
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

CAR-T cell therapy is a highly personalized cancer treatment. Its core approach involves using genetic engineering to introduce a chimeric antigen receptor (CAR) gene that specifically recognizes tumor antigens into a patient''s T cells, transforming them into CAR-T cells. These modified T cells are able to accurately recognize and efficiently kill tumor cells expressing specific antigens, thereby achieving targeted tumor treatment. The CAR-T production process primarily includes initial T cell isolation and enrichment, T cell activation and expansion, CAR gene transfer using viral or non-viral vector systems, in vitro CAR-T cell expansion, and final processing and cryopreservation of the resulting cell product.

In the CAR-T cell production process, stable transfection is a prerequisite for stable CAR expression in effector T cells. Currently, the mainstream gene delivery method for CAR-T remains viral transduction, primarily using gamma-retrovirus and lentivirus. However, in recent years, gamma-retroviral transduction has been gradually replaced by lentiviral transduction in clinical trials due to issues such as the risk of insertional oncogenesis, inability to infect non-dividing cells, and low viral titers. Therefore, lentiviral packaging technology plays an indispensable role in the preparation of CAR-T cells. As the core link of CAR-T cell therapy, lentiviral packaging technology plays a vital role in the field of tumor immunotherapy.

Characterizing intercellular communication and tracking its changes over time is critical to understanding the coordination of biological processes that mediate normal development, disease progression, and responses to perturbations such as therapeutics. Existing tools are unable to capture time-dependent cell-to-cell interactions and rely primarily on databases compiled from limited contexts. Here, researchers introduce DIISCO, a Bayesian framework designed to characterize the temporal dynamics of cellular interactions using single-cell RNA sequencing data from multiple time points. The approach leverages structured Gaussian process regression to reveal time-resolved interactions between different cell types based on their co-evolution, incorporating prior knowledge of receptor-ligand complexes. Researchers demonstrate the interpretability of DIISCO in both simulated data and new data collected from T cells co-cultured with lymphoma cells, demonstrating its potential to reveal dynamic cell-cell cross talk.

To demonstrate the application of DIISCO to biological data, the researchers generated single-cell data from a controlled in vitro experimental setting. Specifically, green fluorescent protein (GFP)-transduced anti-CD19 (CAR-T cells) were co-cultured with MEC1 cells, a CD19-expressing B cell (chronic lymphocytic leukemia [CLL]) leukemia cell line, as CAR-T cell targets (Figure 1A). CD19 CAR-T cells were generated by transducing healthy donor T cells with a third-generation lentiviral vector encoding a bicistronic construct containing FMC63 CD19 scFv-CD28-CD3ZETA (currently known as CD247) and either GFP or FMC63 CD19 scFv-41BB-CD3ZETA. Four biological replicates were analyzed using scRNA-seq at 10 time points over 24 hours, resulting in high-quality data for 49,283 total cells. The data showed changes in composition over time, prompting the use of this dataset as a test case for studying temporal interactions with DIISCO (Figure 1B). By clustering and examining the expression of a curated set of genes, the researchers identified four major cell types (meta-clusters): cancer cells, exhausted CD8+ T cells, activated CD8+ T cells, and other CD8+ T cells that had neither activation nor exhaustion markers. MEC1 cancer cells were annotated based on the expression of CD19 and CD79A. T cells were annotated based on the expression of CD3E, CD3D, and CD8A. Activated T cells were defined by the expression of CD69, CD27, and CD28, while exhausted cells were defined by the expression of TIGIT, PDCD1, TGFB1, and LAG3 (Figure 1C-E). Clusters that were positive for both T cell and MEC1 gene markers were removed as doublets.

Figure 1. CAR T experimental setup and data preprocessing.Figure 1. CAR T experimental setup and data preprocessing. (Park C, et al., 2024)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Consistent Lot-to-Lot Performance

Having used three separate lots over 18 months, we observed remarkable consistency in titer, transduction efficiency, and resulting CAR-T cell function. This reliability is essential for longitudinal studies and reduces experimental variability.

United States

06/12/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER